Active Not Recruiting PHASE1 INTERVENTIONAL 5-arm NCT05364073

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Sponsor: ArriVent BioPharma, Inc.

Conditions Advanced Non-Small Cell Lung Cancer EGFR Exon 20 Mutations EGFR Uncommon Mutations, Including G719X and S768I HER2 Exon 20 Mutations Metastatic Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer (NSCLC)

Interventions Furmonertinib

Updated 24 times since 2022 Last updated: Mar 11, 2026 Started: Jun 30, 2022 Primary completion: Jun 3, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Non-Small Cell Lung Cancer and EGFR Exon 20 Mutations, this trial is ongoing. The trial is conducted by ArriVent BioPharma, Inc. and has accumulated 24 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

24 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1
Sep 2025 — Mar 2026 [monthly]

Active Not Recruiting PHASE1
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Jan 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE1

▶ Show 19 earlier versions

Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Jul 2023 — Dec 2023 [monthly]

Recruiting PHASE1
May 2023 — Jul 2023 [monthly]

Recruiting PHASE1
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE1
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE1
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE1
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE1
Jun 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ArriVent BioPharma, Inc.

Data source: ArriVent BioPharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Barcelona, Spain , Beijing, China , Blacktown, Australia , Celebration, United States , Changchun, China , Chaoyang, China , Chiba, Japan , Chongqing, China , Chūō, Japan and 29 more locations